Morgan Stanley: Gives HANSOH PHARMA a "Buy" rating with a target price of HKD 24
Morgan Stanley released a research report stating that it has given HANSOH PHARMA an "Overweight" rating, with a target price of HKD 24. HANSOH PHARMA announced that it has entered into a global exclusive licensing agreement with Merck, granting it global exclusive rights to develop, manufacture, and commercialize the preclinical oral small molecule GLP-1 receptor agonist HS-10535, involving an upfront payment of USD 112 million, as well as milestone payments and royalties based on product sales of up to USD 1.9 billion
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments